Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
As of close of business last night, Arcutis Biotherapeutics Inc’s stock clocked out at $10.47, up 2.15% from its previous closing price of $10.25. In other words, the price has increased by $2.15 from its previous closing price. On the day, 2.28 million shares were traded. ARQT stock price reached its highest trading level at $10.76 during the session, while it also had its lowest trading level at $10.04.
Ratios:
To gain a deeper understanding of ARQT’s stock, we examine its different ratios. For the most recent quarter (mrq), Quick Ratio is recorded 2.38 and its Current Ratio is at 2.46. In the meantime, Its Debt-to-Equity ratio is 1.33 whereas as Long-Term Debt/Eq ratio is at 0.69.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Jefferies on August 28, 2024, initiated with a Buy rating and assigned the stock a target price of $15.
On January 03, 2024, Mizuho Upgraded its rating to Buy which previously was Neutral and also upped its target price recommendation from $4 to $8.
Mizuho Downgraded its Buy to Neutral on October 26, 2023, whereas the target price for the stock was revised from $57 to $4.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Nov 11 ’24 when Curran Terrie sold 8,687 shares for $10.85 per share. The transaction valued at 94,238 led to the insider holds 10,139 shares of the business.
Curran Terrie bought 8,687 shares of ARQT for $94,238 on Nov 11 ’24. On Nov 04 ’24, another insider, Matsuda Masaru, who serves as the insider of the company, sold 5,015 shares for $8.68 each. As a result, the insider received 43,551 and left with 178,273 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ARQT now has a Market Capitalization of 1225461120 and an Enterprise Value of 1103073920. For the stock, the TTM Price-to-Sale (P/S) ratio is 8.83 while its Price-to-Book (P/B) ratio in mrq is 7.82. Its current Enterprise Value per Revenue stands at 7.952 whereas that against EBITDA is -6.148.
Stock Price History:
Over the past 52 weeks, ARQT has reached a high of $13.17, while it has fallen to a 52-week low of $1.76. The 50-Day Moving Average of the stock is 8.34%, while the 200-Day Moving Average is calculated to be 11.66%.
Shares Statistics:
It appears that ARQT traded 2.12M shares on average per day over the past three months and 2667360 shares per day over the past ten days. A total of 117.05M shares are outstanding, with a floating share count of 101.93M. Insiders hold about 12.91% of the company’s shares, while institutions hold 99.68% stake in the company. Shares short for ARQT as of 1730332800 were 27755696 with a Short Ratio of 13.07, compared to 1727654400 on 27129867. Therefore, it implies a Short% of Shares Outstanding of 27755696 and a Short% of Float of 29.349999999999998.
